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Abstract
Pulmonary hypertension (PH) is characterized by the increase of the mean pulmonary arterial
pressure in the lung circulation. Despite the large number of experimental and clinical studies
conducted on pulmonary hypertension, there is no comprehensive work that analyzed the
global research activity on PH so far. We retrieved the bibliometric data of the publications on
pulmonary hypertension for two periods from the Web of science database. Here, we set the
first investigation period from 1900 to 2007 (t1) due to the cited half life of articles and the
relating difficulties to interpret the citation parameters. The second evaluation period (t2) cov-
ers the time interval from 2008 onwards including the year 2015. The data were analyzed and
processed to density-equalizing maps using the NewQIS platform. A total number of 18,986
publications were identified in t1 that come from 85 countries. The US published the highest
number of publications (n = 7,290), followed by the UK, Germany, Japan and France. In t2
19,676 items could be found worked out by 130 countries. The raking started just the same
with the USA as most publishing nation with 7,127 publications on PH, followed by the UK
and Germany. Japan fell back on 6th place, whereas China came into view on the 5th position.
Analyzing the average citation rate as a parameter for research quality, Mexico reached the
highest value in t1 and Ireland in t2. While, the country specific h-index underlined the leading
position of the US research in both evaluation periods again. The average number of interna-
tional collaboration items was expanding from none in 1978 to 530 items in 2015 with the
USA as the country with the highest number of collaboration articles. The present study is the
first large scale density-equalizing mapping and scientometric analysis of global PH research
activity. Our data draw a sketch of the global research architecture in this field, indicating a
need for specific research programs in countries with a lower human development index.
Introduction
Pulmonary hypertension (PH) is characterized by the increase of the mean pulmonary arterial
pressure (mPAP) in the lung-circulation. Due to the chronically overload of the right ventricle
the heart is affected by a PH and is often developing a chronic cor pulmonale which can lead to
a right heart failure [1]. PH was previously classified into 2 categories: 1) primary pulmonary
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hypertension; or 2) secondary pulmonary hypertension according to the presence of identified
causes or risk factors [2]. Since the second World Symposium on pulmonary hypertension
(WSPH) held in Evian, in 1998, a clinical classification was established in order to individualize
different categories of PH sharing similar pathological findings, similar hemodynamic charac-
teristics and, similar management. In the following symposia (Venice—2003, California—2008)
several modifications of treatment strategies were introduced caused by the reflection of the sci-
entific progress. During 5th WSPH in Nice in 2013 substantial changes of the classification and
the treatment of PH has been adopted and some child specific items has been added [3–12].
Concerning the epidemiology of PH, a number of registries provided important information
about epidemiologic and phenotypic features of PH. In this respect, changes in the phenotype
were observed in the past decades, including changes in survival, age, sex, and comorbidities
[13–17]. Despite the relatively young mean age of patients with idiopathic PAH in the first pub-
lished registry with 36 ± 15 years [18], PAH is currently more frequently found in elderly indi-
viduals. This leads to current mean ages between 45 ±17 and 65 ± 15 years at diagnosis [13–17].
Importantly, the age of diagnosis in PH is different according to the group of disorders that
cause PH. For example, in the REHAP registry, the age at diagnosis of pulmonary arterial
hypertension was 45 ±17 years, however, patients with chronic tromboembolic pulmonary
hypertension were diagnosed at age 61± 15 years.
Next to this change in epidemiologic features, also the pathophysiological concept of PH has
changed from a solely vasoconstrictive to a vasoproliferative genesis recent years [19–22]. Thereby
new pharmacological targets have been identified that have changed the therapeutic strategy [20,
23–27]. The current scheme of therapy is elegantly described in several recent reviews and con-
sists of drug classes including prostaglandins, phosphodiesterase-5-inhibitors, endothelial-recep-
tor blockers and guanylatcyclase-stimulators [28–35]. After failure of pharmacological treatments
lung transplantation remains as final and difficult therapeutic option [36–38].
During the last years enormous research efforts have been undertaken to improve our
knowledge of the pathophysiology of the disease in order to provide new options for treatment
and diagnostics. However, the enormous amount of data has not been analyzed in a profound
manner concerning global research activities as in other fields [39]. Therefore, PH was in-
cluded to the international study project “New quality and quantity indices in science” (New-
QIS) [40, 41]. It was the aim of the present study to combine advanced density-equalizing
algorithms and scientometric tools to draw a sketch of the global PH research architecture in
the defined period between 1900 and 2007.
Methods
Data source
Data was retrieved from the Web of Science (WoS) database that is provided by the Thomson
Reuters Institute for Scientific Information (ISI). The original data is publicly accessible
via the link: http://www.med.uni-frankfurt.de/institut/arbeitsmedizin/Public-Repository/
PulHypertension/index.html
Search strategies
In order to approximate the overall number of publications on pulmonary hypertension the
following phrase was entered in the search field: „pulmonary hypertens”OR „pulmonary arte-
rial hypertens“. The Boolean operator ‘OR’ joined the terms together, the asterisk () was
used to cover all possible word endings such as hypertension, hypertensive or others. Due to
the cited half life of articles that set the maximum of biomedical citations approximately at five
to eight years after their publication, the analyzed first time span (t1) included the period from
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1900 to 2007. The following period covered the time between 2008 and 2015 (t2) to assess the
more current developments of the publication outcome.
Citation quantities
The findings from the search process were analyzed with the ‘citation report’ function to deter-
mine the citations per year as well as the modified h-index calculated in a PH-specific manner
and adjusted also to the publishing countries. Additionally, the citation rate which is the sum of
the total times cited divided by the number of items in the set, has been calculated and analyzed.
Data categorization
The bibliometric data from the search process results were downloaded in units of 500 publica-
tions by using the ‘output records‘ and ‘save as plain text’ functions from WoS. The digital
information was transformed into an Access-Database format and the items were software-
controlled analyzed for the origin of the publications by using the author address as the crite-
rion for the publishing country. Furthermore, the data files were examined concerning a vari-
ety of different parameters e.g. the publication date, the authors and the publishing journals.
Density-equalizing mapping
Density equalizing map projections (DEMP) were calculated and generated for this study [42].
In brief, to visualize the distribution of the overall number of published items and the average
citation rate in a country specific manner, density-equalizing mapping procedures were calcu-
lated using the algorithm developed by Gastner and Newman [43]. In these calculations, the
area of each country was scaled in proportion to a particular variable, i.e. the number of pub-
lished items. This resizing procedure of the countries leads to a modified and distorted global
map presenting the geographic allocation of a specific parameter.
Quality criteria
To evaluate both, quantity and quality of a publishing institution, a modified version of h-
index was established. In brief, the h-index of h can be calculated, if h of all publications
received at least h citations each [44]. The index, normally used for the author’s overall scien-
tific output, refers in this study only to the PH-specific publications and has been employed on
the assessment of the publishing countries.
The Impact-Factor is defined as the average number of citations per year given to those
publications from an institution, that were published during the two preceding years [45]. The
Impact-Factor was used to compare the most productive journals among each other.
Analysis of cooperation
To evaluate the international cooperation in publications, the data from the created Access-Data-
base were software controlled analyzed to differentiate between cooperation-publications and sin-
gle-country articles. The isolated publications from international cooperation were analyzed
regarding the quantity of the cooperation between every single publishing country and another.
Results
Analysis of origin
During the first evaluation period from 1900 to 2007 (t1), 18,986 published items (n) were
worked out and included in the Web of Science database. They originated from 85 countries
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with the USA being the most prolific one having contributed in 40,7% (n = 7,290) of the total
amount. The UK, Germany, Japan and France had more than 1,000 publications. The cumu-
lated publications of the top five countries encompassed 67,8% of all indexed articles, taking
into account that 1,396 publications were international collaborations and 2,907 items could
not be assigned to a certain country (15.3%). The DEMP of this set of data visualizes the USA
being responsible for the majority of the research efforts by far (Fig 1A).
From 2008 to 2015 (t2) a similar picture can be shown (Fig 1B). The USA published also in
this time interval the most items with a contribution in 36,2% (n = 7,127) of the 19,676 items.
The top five countries achieved even 72.9% of the overall publications. The international col-
laborations resulted in 3,442 items. Only 3.4% could not be assigned to a specific country in t2.
The first Article was published in the year 1934 but in the following years the output was
inconstant, only 143 items were published until the year 1958. From that time on the numbers
of items steadily increased until a peak was reached with 1,432 publications in the year 2005.
The annual increase was interrupted by intermittent drops of the number of published items
in 1987–1990 and 2000–2002 (Fig 2A). During the period from 2008–2015 the figures raised
more from 1,702 to 3,011 articles in 2013. In the last two years of the evaluation period a small
decrease to 2,533 items could be stated (Fig 2B).
Citation parameters
To determine the research quality of the countries the average number of citations per item
was used as criteria for quality. For visualization, the DEMP technique was used to display cita-
tion rate (cR), with a threshold of at least thirty publications per country. When analyzing all
country-specific articles in t1, Mexico had the highest citation rate (cR = 23.29), Canada
ranked second (cR = 20.69) and Belgium third (cR = 20.41). The most productive country, the
USA achieved only a value of 18.12 and assumed so only position 23. Europe’s leading coun-
tries, the UK (cR = 18.71), Germany (cR = 13.54) and France (cR = 18.35) occupied the same
sequence as with the number of published items (Fig 3A).
In t2 (2008–2015) Ireland achieved the highest value with cR = 25.71. Second ranked Hun-
gary (cR = 19.51) and the third place claimed Sweden (cR = 18.1). The European countries
that reached high values apart from that are Switzerland (cR = 17.73), and Belgium (cR =
17.72). The USA–as in t1 –had not a leading position and attained only a cR of 11.56. Mexico
dropped to an even lower position with a cR = 11,16 (Fig 3B).
In comparison to the research output quantity as showed in Fig 2, big differences in the
apportionment of the surface area in proportion to the average citations per item of each coun-
try can be visualized (Fig 3).
As a further parameter for the research quality of the publishing countries, modified the h-
index (hI) was calculated for each country. With the highest modified index by far (hI = 132)
in t1 (Fig 4A), the USA ranked first followed by the UK (hI = 73) and France (hI = 67). In t2
the two leading positions were also claimed by the USA (hI = 101) and the UK (hI = 70). Ger-
many followed on the third position (hI = 69), whereas in t1 it reached only the 5th position
(hI = 59). France could be placed 4th (hI = 66) in t2 (Fig 4B).
Cooperation analysis
The analysis of average number of international collaborations show that they grew from none
in the year 1978 to 177 items in the year 2007 (t1) and furthermore, from 236 collaborations in
2008 to 530 items in 2015 (t2). In particular, the abrupt rise of collaborations between the
years 2003 and 2004 from 100 to 164 and the high number in 2013 are remarkable (Fig 5A
and 5B).
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Additionally, the international collaboration network was reviewed and the number of col-
laborations for each country was calculated. In both evaluation periods, the USA was the coun-
try with the most research partnerships and the largest number of collaboration articles (cA).
Fig 1. Density Equalizing Map Projection, Publication output. A) 1900–2007 B) 2008–2015, Legend = number of publications.
doi:10.1371/journal.pone.0169238.g001
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Fig 2. No. of PH-specific publications over the time. A) 1900–2007 B) 2008–2015
doi:10.1371/journal.pone.0169238.g002
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Fig 3. Density Equalizing Map Projection, citation analysis. A) 1900–2007 B) 2008–2015, Legend = citation rate.
doi:10.1371/journal.pone.0169238.g003
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Fig 4. Modified h-Index of the most publishing countries. A) 1900–2007 B) 2008–2015
doi:10.1371/journal.pone.0169238.g004
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Fig 5. No. of authors per publication, no. of cooperation articles and no. of references over the time. A) 1900–2007 B) 2008–
2015
doi:10.1371/journal.pone.0169238.g005
Research on Pulmonary Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0169238 January 4, 2017 9 / 17
In t1 the strongest partner of the USA was Canada with 164 USA/Canadian collaborations, fol-
lowed by the USA/UK (cA = 140), USA/France (cA = 110) and USA/Germany (cA = 109). In
total, the USA collaborates with 54 different countries in an amount of 1,139 collaboration
articles.
In t2 the strongest partner of the USA was the UK with an amount of 372 collaboration
articles, followed by USA/Germany (cA = 321), USA/Canada (cA = 313) and USA/Italy
(cA = 262). The USA worked out a total of 3,262 collaboration articles with 93 different coun-
tries in t2.
The spider charts in Fig 6 illustrate the international networks of both investigation periods
from a threshold of 20 collaboration articles at least. Even at first glance, it can be recognized
that the total amount of collaboration with more than 20 joint works has increased substan-
tially in t2 (Fig 6B).
To differentiate between the publication output of the countries worked out together with
other countries and the individual achievement of each country, the citation rate (cR) for the
cooperation and single-country items as well as the combined accomplishment has been deter-
mined (Fig 7). The analysis of the fraction of the top countries regarding single-country items,
cooperation-items and the combined value of the average citations of the different forms of
publications show, that the well cited cooperation-items of Mexico in t1 (cR = 51.94) were
responsible for the high value in combined-items (cR = 23.29). Concerning the citation rate
for the single-country publications, the USA showed the highest rate (cR = 17.03) followed by
Canada (cR = 16.74) and Sweden (cR = 15.96) in t1 (Fig 7A).
In t2 Ireland reached the highest citation rate for the cooperation items that are–similar to
Mexico in t1 –responsible for the high overall citation rate of the combined values. Sweden
received the highest rate for the individual country output (cR = 14.33), followed by Denmark
(cR = 10.30) and the Netherlands with cR = 10.18 (Fig 7B).
Analysis of the number of references and participating authors
Furthermore, the number of references and the number of the participating authors per pub-
lished item were determined over the time. The average number of authors per item rose in
the first period t1 from initially 3.75 in the year 1978 to 5.52 in 2007 (Fig 5A) and in t2 from
5.72 to 6.73 (Fig 5B).
In the same mode, the average number of quoted references per published item increased.
Starting in 1978 with 16.46 references, the number duplicated to more than 47.76 in 2007. This
level had not been reached in t2 with a slight increase from 40.7 in 2008 to 45.54 in 2015.
Discussion
During the past decades, medical investigation has been spurred by a number of revolutionary
new insights into pathogenetic and pathophysiologic mechanisms of pulmonary hypertension
that led to significant changes in the management of the disease. However, despite these
advantages in science and clinics a precise scientometric analysis of research activity has not
been performed so far. Therefore, the NewQIS project elected PH as a research focus and per-
formed a combined density-equalizing and scientometric study.
By the selection of WoS as data source a methodical bias cannot be excluded. Not all jour-
nals publishing on PH are listed. Particularly publications of national associations or recently
founded journals have not found entry into WoS. Additionally, a majority of English-publish-
ing journals can be found, so that a preference for these journals can be stated. Therefore,
English-speaking countries should have an advantage.
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Fig 6. International collaborations. A) 1900–2007 B) 2008–2015, Legend = No. of collaboration articles, threshold: 20 items per
country, colors and bar thickness encode amount of cooperation, numbers in brackets (publications / collaboration articles).
doi:10.1371/journal.pone.0169238.g006
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A total of 38.662 publications related to PH were identified between 1900 and 2015 with a
progressive increase since the beginning of the 1980’s and an abrupt rise from the year 1992
on. The maximum was reached in 2013 with 3011 publications. In principle, this picture
reflects the usual tendency regarding the development of publication output in the biomedical
Fig 7. Country specific citation rate for single country articles (single), collaborations (cooperation) and all
published items (combined). A) 1900–2007 B) 2008–2015
doi:10.1371/journal.pone.0169238.g007
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sciences as shown in previous studies [46–48]. Additionally, this development might be used
as indicator for an augmented interest in PH. On the one hand, great scientific advances such
as the identification of nitric oxide as a vasodilative agent, the direct inhalation of nitric oxide
(NO) for selective pulmonary vasodilation and the first studies on endothelin-1 antagonists
should be mentioned in this respect [49, 50]. Furthermore, it can be assumed that major politi-
cal health events like the 3rd WSPH in 2003 had an impact on the PH-research output [11,
51]. The high values in 2013 derive certainly from the importance of the 5th WSPH held in
Nice that delivered new aspects on PH leading to important changes regarding its treatment
and classification [12].On the other hand, the steep increase in 1991 can be technically
explained by the implementation of abstracts and keywords in WoS [52].
85 countries had been publishing on PH until 2007 and 130 from 208 onwards. The USA as
leading country published the most articles on PH in both evaluation intervals (t1: n = 7,290;
t2: 2,127). Only the combined publication output of Europe countries achieved a comparable
amount. A relatively small number of countries was responsible for the majority of research on
PH. The top three ranking of US, UK, Germany in t1 is not a unique pattern of PH research
[53, 54]. It is also visible in numerous other respiratory fields [47] as well as in cardiologic
fields [55, 56], in infectious diseases [46, 57], or public health issues [58, 59]. Until 2007 (t1)
Japan and France followed the first three countries, whereas in t2 France and China occupied
the next places, that means that China replaced Japan in ranking of the top five. This is cer-
tainly caused by the development of the Chinese economy in the last three decades, during
which China has steadily increased their expenditures for research and development (R&D)
and funded many scientific programmes that had also an enormous impact on the overall
research output. Even in 2012 China invested nearly as much in R&D as Europe. The OECD
estimated that China will be the country with the highest R&D expenditures in 2019 world-
wide [60].
The leading position of the USA is underlined by the analysis of the international networks.
The USA is involved in the majority of collaborations and at the same time the closest partner
for many countries. By contrast, regarding the country’s citation rates, Mexico showed the
highest value due to few high cited cooperation articles in t1. Ireland achieved the highest rate
in t2. Here, undoubtedly their high cited collaboration work in relation to their overall publica-
tion output also accounts for. The University College of Dublin took part in the second most
cited article on the alterations of the clinical classification in the aftermath of the 4th WSPH in
2009 among nine other countries. This article titled “Updated Clinical Classification of Pulmo-
nary Hypertension” by Simonneau et al. [61] has been cited 969 times alone at the time of
retrieving the articles. The most cited article (1,337 citations) has been published by Galie et al.
from the University of Bologna (Italy) also in 2009 “Guidelines for the diagnosis and treatment
of pulmonary hypertension” [62]. This contributes definitely to the Italian’s placement among
the best ten countries regarding their citation rate in t2.
The application of the PH-specific h-index, unlike the citation rates, diminish the overvalu-
ation of few or single outstanding articles. This was confirmed by the findings that dies not put
Mexico, respectively Ireland, among the highest ranked countries in this respect. Here, the
USA again achieved the highest value in both evaluation periods.
While comparing the two evaluation periods, a trend towards a higher number of collabo-
rations and the involvement of more nations worldwide can be stated. This underlines the
importance of the global networking and its positive consequences [63].
In summary, the present study provides an in-depth scientometric analysis of the publica-
tions on PH since 1900 till 2015 in two separate time intervals, so that we can determine, exam-
ine and discuss changes in the publication activity. Regarding the research output, since 1934 a
progressive increase could be shown that lead to an equally increase of citations. Using DEMP
Research on Pulmonary Hypertension
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algorithms, a picture of the global PH research architecture was generated. The data indicates
a need for specific research programs in countries with a lower human development index.
Acknowledgments
We thank G Volante for technical assistance, B Kloft and C Scutaru for their pioneering work
during the establishment of the NewQIS platform.
Author Contributions
Conceptualization: DAG DK MG.
Data curation: MG DK DAG.
Formal analysis: MG MS.
Investigation: MG MS DK.
Methodology: DK DAG.





Visualization: MG AG DK.
Writing – original draft: MG.
Writing – review & editing: MG MS AG DK DAG.
References
1. Han MK, McLaughlin VV, Criner GJ, Martinez FJ. Pulmonary diseases and the heart. Circulation. 2007;
116(25):2992–3005. doi: 10.1161/CIRCULATIONAHA.106.685206 PMID: 18086941
2. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hyperten-
sion. Circulation. 2008; 118(21):2190–9. doi: 10.1161/CIRCULATIONAHA.107.723007 PMID:
19015413
3. Ghofrani HA, Distler O, Gerhardt F, Gorenflo M, Grunig E, Haefeli WE, et al. Treatment of pulmonary
arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011.
International journal of cardiology. 2011; 154 Suppl 1:S20–33. Epub 2012/01/10.
4. Grunig E, Barner A, Bell M, Claussen M, Dandel M, Dumitrescu D, et al. Non-invasive diagnosis of pul-
monary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus
Conference 2011. International journal of cardiology. 2011; 154 Suppl 1:S3–12. Epub 2012/01/10.
5. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, et al. Pulmonary hyperten-
sion due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference
2011. International journal of cardiology. 2011; 154 Suppl 1:S45–53. Epub 2012/01/10.
6. Opitz CF, Blindt R, Blumberg F, Borst MM, Bruch L, Leuchte HH, et al. Pulmonary hypertension: Hemo-
dynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011. Interna-
tional journal of cardiology. 2011; 154 Suppl 1:S13–9. Epub 2012/01/10.
7. Rosenkranz S, Bonderman D, Buerke M, Felgendreher R, ten Freyhaus H, Grunig E, et al. Pulmonary
hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Confer-
ence 2011. International journal of cardiology. 2011; 154 Suppl 1:S34–44. Epub 2012/01/10.
8. Rosenkranz S, Ghofrani HA, Grunig E, Hoeper MM. Cologne Consensus Conference on pulmonary
hypertension. International journal of cardiology. 2011; 154 Suppl 1:S1–2. Epub 2012/01/10.
Research on Pulmonary Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0169238 January 4, 2017 14 / 17
9. Wilkens H, Lang I, Behr J, Berghaus T, Grohe C, Guth S, et al. Chronic thromboembolic pulmonary
hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011.
International journal of cardiology. 2011; 154 Suppl 1:S54–60. Epub 2012/01/10.
10. Yamamura K, Nagata H, Ikeda K, Ihara K, Hara T. Efficacy of bosentan therapy for segmental pulmo-
nary artery hypertension due to major aortopulmonary collateral arteries in children. International journal
of cardiology. 2012; 161(1):e1–3. Epub 2012/03/31. doi: 10.1016/j.ijcard.2012.03.021 PMID: 22459378
11. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification
of pulmonary hypertension. Journal of the American College of Cardiology. 2004; 43(12 Suppl S):5S–
12S.
12. Galie N, Simonneau G. The Fifth World Symposium on Pulmonary Hypertension. Journal of the Ameri-
can College of Cardiology. 2013; 62(25 Suppl):D1–3. doi: 10.1016/j.jacc.2013.10.030 PMID: 24355633
13. Escribano-Subias P, Blanco I, Lopez-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Sur-
vival in pulmonary hypertension in Spain: insights from the Spanish registry. The European respiratory
journal. 2012; 40(3):596–603. Epub 2012/03/01. doi: 10.1183/09031936.00101211 PMID: 22362843
14. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting sur-
vival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term
Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122(2):164–72.
Epub 2010/06/30. doi: 10.1161/CIRCULATIONAHA.109.898122 PMID: 20585012
15. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idio-
pathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management
era. Circulation. 2010; 122(2):156–63. Epub 2010/06/30. doi: 10.1161/CIRCULATIONAHA.109.
911818 PMID: 20585011
16. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial
hypertension: a reappraisal of the NIH risk stratification equation. The European respiratory journal.
2010; 35(5):1079–87. Epub 2009/12/25. doi: 10.1183/09031936.00072709 PMID: 20032020
17. Lee WT, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK. Predicting survival in pulmo-
nary arterial hypertension in the UK. The European respiratory journal. 2012; 40(3):604–11. Epub 2012/
05/05. doi: 10.1183/09031936.00196611 PMID: 22556026
18. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary
hypertension. A national prospective study. Annals of internal medicine. 1987; 107(2):216–23. Epub
1987/08/01. PMID: 3605900
19. Eickelberg O, Seeger W. Pulmonary hypertension: pathophysiology, genetics and functional genomics.
Internist. 2005; 46(7):759-+. doi: 10.1007/s00108-005-1431-8 PMID: 15918053
20. Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative
agents. American journal of respiratory and critical care medicine. 2002; 166(10):1308–9. doi: 10.1164/
rccm.2208008 PMID: 12421739
21. Maron BA, Loscalzo J. Pulmonary hypertension: pathophysiology and signaling pathways. Handbook
of experimental pharmacology. 2013; 218:31–58. Epub 2013/10/05. doi: 10.1007/978-3-642-38664-0_
2 PMID: 24092335
22. Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension:
pathophysiology. European respiratory review: an official journal of the European Respiratory Society.
2010; 19(115):59–63. Epub 2010/10/20.
23. McLaughlin VV. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Euro-
pean respiratory review: an official journal of the European Respiratory Society. 2011; 20(122):262–9.
Epub 2011/12/02.
24. Mathew R. Pulmonary hypertension: current therapy and future prospects. Cardiovascular & hemato-
logical agents in medicinal chemistry. 2011; 9(3):165–82. Epub 2011/08/16.
25. Levinson AT, Klinger JR. Combination therapy for the treatment of pulmonary arterial hypertension.
Therapeutic advances in respiratory disease. 2011; 5(6):419–30. Epub 2011/08/19. doi: 10.1177/
1753465811411602 PMID: 21849335
26. Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
Cardiology. 2011; 120(3):157–65. Epub 2012/01/04. doi: 10.1159/000334431 PMID: 22212696
27. Hoeper MM, Dinh-Xuan AT. Combination therapy for pulmonary arterial hypertension: still more ques-
tions than answers. The European respiratory journal. 2004; 24(3):339–40. doi: 10.1183/09031936.04.
00072104 PMID: 15358685
28. Baradia D, Khatri N, Trehan S, Misra A. Inhalation therapy to treat pulmonary arterial hypertension.
Pharmaceutical patent analyst. 2012; 1(5):577–88. Epub 2013/11/19. doi: 10.4155/ppa.12.66 PMID:
24236926
Research on Pulmonary Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0169238 January 4, 2017 15 / 17
29. Coeytaux RR, Schmit KM, Kraft BD, Kosinski AS, Mingo AM, Vann LM, et al. Comparative effectiveness
and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.
Chest. 2014; 145(5):1055–63. Epub 2013/12/29. doi: 10.1378/chest.13-1864 PMID: 24371842
30. Gorenflo M, Apitz C, Miera O, Stiller B, Schranz D, Berger F, et al. [Pulmonary hypertension/pulmonary
arterial hypertension in congenital heart disease and therapy of pulmonary arterial hypertension in chil-
dren]. Deutsche medizinische Wochenschrift (1946). 2014; 139 Suppl 4:S166–70. Epub 2014/12/10.
31. Klose H, Opitz C, Bremer H, Ewert R, Bonderman D, Rosenkranz S, et al. [Targeted therapy of pulmo-
nary arterial hypertension (PAH)]. Deutsche medizinische Wochenschrift (1946). 2014; 139 Suppl 4:
S142–50. Epub 2014/12/10.
32. McLaughlin VV, Palevsky HI. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary
arterial hypertension. Clinics in chest medicine. 2013; 34(4):825–40. Epub 2013/11/26. doi: 10.1016/j.
ccm.2013.09.003 PMID: 24267307
33. Pugh ME, Hemnes AR, Robbins IM. Combination therapy in pulmonary arterial hypertension. Clinics in
chest medicine. 2013; 34(4):841–55. Epub 2013/11/26. doi: 10.1016/j.ccm.2013.08.007 PMID:
24267308
34. Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, et al. Pharmacologic therapy for pul-
monary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014; 146
(2):449–75. Epub 2014/06/18. PubMed Central PMCID: PMCPMC4137591. doi: 10.1378/chest.14-
0793 PMID: 24937180
35. Wu Y, O’Callaghan DS, Humbert M. An update on medical therapy for pulmonary arterial hypertension.
Current hypertension reports. 2013; 15(6):614–22. Epub 2013/10/15. doi: 10.1007/s11906-013-0394-8
PMID: 24122306
36. Norfolk SG, Lederer DJ, Tapson VF. Lung transplantation and atrial septostomy in pulmonary arterial
hypertension. Clinics in chest medicine. 2013; 34(4):857–65. Epub 2013/11/26. doi: 10.1016/j.ccm.
2013.09.002 PMID: 24267309
37. Lordan JL, Corris PA. Pulmonary arterial hypertension and lung transplantation. Expert review of respi-
ratory medicine. 2011; 5(3):441–54. Epub 2011/06/28. doi: 10.1586/ers.11.21 PMID: 21702664
38. Kusano KF. Treatment for pulmonary hypertension including lung transplantation. General thoracic and
cardiovascular surgery. 2011; 59(8):538–46. Epub 2011/08/19. doi: 10.1007/s11748-010-0747-z
PMID: 21850579
39. Kempny A, Fernandez-Jimenez R, Tutarel O, Dimopoulos K, Uebing A, Shiina Y, et al. Meeting the
challenge: the evolving global landscape of adult congenital heart disease. International journal of cardi-
ology. 2013; 168(6):5182–9. Epub 2013/08/27. doi: 10.1016/j.ijcard.2013.07.198 PMID: 23972963
40. Groneberg-Kloft B, Quarcoo D, Scutaru C. Quality and quantity indices in science: use of visualization
tools. EMBO reports. 2009; 10(8):800–3. Epub 2009/08/04. PubMed Central PMCID:
PMCPMC2726685.
41. Groneberg-Kloft B, Fischer TC, Quarcoo D, Scutaru C. New quality and quantity indices in science
(NewQIS): the study protocol of an international project. Journal of occupational medicine and toxicol-
ogy (London, England). 2009; 4:16. Epub 2009/06/27. PubMed Central PMCID: PMCPMC2708171.
42. Gerber A, Groneberg DA, Klingelhofer D, Bundschuh M. Gout: a critical analysis of scientific develop-
ment. Rheumatology international. 2013; 33(11):2743–50. Epub 2013/06/26. doi: 10.1007/s00296-013-
2805-1 PMID: 23797780
43. Gastner MT, Newman MEJ. Diffusion-based method for producing density-equalizing maps. Proceed-
ings of the National Academy of Sciences of the United States of America. 2004; 101(20):7499–504.
doi: 10.1073/pnas.0400280101 PMID: 15136719
44. Hirsch JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci U S A.
2005; 102(46):16569–72. Epub 2005/11/09. PubMed Central PMCID: PMCPMC1283832. doi: 10.
1073/pnas.0507655102 PMID: 16275915
45. Garfield E. The history and meaning of the journal impact factor. Jama-Journal of the American Medical
Association. 2006; 295(1):90–3.
46. Fricke R, Uibel S, Klingelhoefer D, Groneberg DA. Influenza: a scientometric and density-equalizing
analysis. BMC infectious diseases. 2013; 13:454. PubMed Central PMCID: PMCPMC3851602. doi: 10.
1186/1471-2334-13-454 PMID: 24079616
47. Gerber A, Klingelhoefer D, Groneberg DA, Bundschuh M. Silicosis: geographic changes in research: an
analysis employing density-equalizing mapping. Journal of occupational medicine and toxicology (Lon-
don, England). 2014; 9(1):2. Epub 2014/01/21. PubMed Central PMCID: PMCPMC3906744.
48. Van Noorden R. Global scientific output doubles every nine years. Nature News Blog. 2014.
Research on Pulmonary Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0169238 January 4, 2017 16 / 17
49. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vaso-
dilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991; 83(6):2038–47. PMID:
2040056
50. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hyper-
tension: marker or mediator of disease? Annals of internal medicine. 1991; 114(6):464–9. PMID:
1994793
51. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23–
25, 2003. Journal of the American College of Cardiology. 2004; 43(12 Suppl S):1S–90S.
52. Science Wo. Science Citation Index Expanded Coverage [cited 2009]. Available from: http://images.
isiknowledge.com/WOK46/help/WOS/h_database.html—ssci.
53. Groneberg-Kloft B, Scutaru C, Dinh QT, Welte T, Chung KF, Fischer A, et al. Inter-disease comparison
of research quantity and quality: bronchial asthma and chronic obstructive pulmonary disease. The
Journal of asthma: official journal of the Association for the Care of Asthma. 2009; 46(2):147–52. Epub
2009/03/03.
54. Groneberg-Kloft B, Scutaru C, Fischer A, Welte T, Kreiter C, Quarcoo D. Analysis of research output
parameters: density equalizing mapping and citation trend analysis. BMC health services research.
2009; 9:16. Epub 2009/01/28. PubMed Central PMCID: PMCPMC2672943. doi: 10.1186/1472-6963-9-
16 PMID: 19171075
55. Vitzthum K, Scutaru C, Quarcoo D, Mache S, Groneberg DA, Schoffel N. Cardiac insufficiency: a critical
analysis of the current publication procedures under quantitative and qualitative aspects. Journal of car-
diothoracic and vascular anesthesia. 2010; 24(4):731–4. Epub 2009/07/28. doi: 10.1053/j.jvca.2009.05.
010 PMID: 19632859
56. Schoffel N, Vitzthum K, Mache S, Groneberg DA, Quarcoo D. The role of endocarditis, myocarditis and
pericarditis in qualitative and quantitative data analysis. International journal of environmental research
and public health. 2009; 6(12):2919–33. Epub 2010/01/06. PubMed Central PMCID:
PMCPMC2800323. doi: 10.3390/ijerph6122919 PMID: 20049235
57. Schmidt S, Bundschuh M, Scutaru C, Klingelhoefer D, Groneberg DA, Gerber A. Hepatitis B: global sci-
entific development from a critical point of view. Journal of viral hepatitis. 2013. Epub 2013/11/12.
58. Vitzthum K, Scutaru C, Musial-Bright L, Quarcoo D, Welte T, Spallek M, et al. Scientometric analysis
and combined density-equalizing mapping of environmental tobacco smoke (ETS) research. PloS one.
2010; 5(6):e11254. Epub 2010/06/29. PubMed Central PMCID: PMCPMC2889821. doi: 10.1371/
journal.pone.0011254 PMID: 20582305
59. Mund M, Kloft B, Bundschuh M, Klingelhoefer D, Groneberg DA, Gerber A. Global research on smoking
and pregnancy-a scientometric and gender analysis. International journal of environmental research
and public health. 2014; 11(6):5792–806. Epub 2014/06/01. PubMed Central PMCID:
PMCPMC4078548. doi: 10.3390/ijerph110605792 PMID: 24879489
60. OECD Science, Technology and Industry Outlook 2014, OECD Publishing, 2014,
61. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical
classification of pulmonary hypertension. Journal of the American College of Cardiology. 2009; 54(1
Suppl):S43–54. doi: 10.1016/j.jacc.2009.04.012 PMID: 19555858
62. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagno-
sis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pul-
monary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory
Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur
Heart J. 2009; 30(20):2493–537. doi: 10.1093/eurheartj/ehp297 PMID: 19713419
63. Adams J. Collaborations: The rise of research networks. Nature. 2012; 490(7420):335–6. doi: 10.1038/
490335a PMID: 23075965
Research on Pulmonary Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0169238 January 4, 2017 17 / 17
